{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:10:50Z","timestamp":1763968250722},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1111\/ced.13357","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:34:40Z","timestamp":1515742480000},"page":"281-285","source":"Crossref","is-referenced-by-count":2,"title":["S\u00e9zary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody"],"prefix":"10.1093","volume":"43","author":[{"given":"T.","family":"Numata","sequence":"first","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nagatani","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mae","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nakasu","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Usuda","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Chukyo Hospital; Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tokyo Medical University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"10.1111\/ced.13357-BIB0001|ced13357-cit-0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1111\/ced.13357-BIB0002|ced13357-cit-0002","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","article-title":"Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"13","author":"Yano","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ced.13357-BIB0003|ced13357-cit-0003","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1111\/ced.13357-BIB0004|ced13357-cit-0004","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/ced.13357-BIB0005|ced13357-cit-0005","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1111\/ced.13357-BIB0006|ced13357-cit-0006","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/ced.13357-BIB0007|ced13357-cit-0007","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ced.13357-BIB0008|ced13357-cit-0008","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of\u00a0regulatory T cells by mogamulizumab, a defucosylated\u00a0anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.13357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.13357\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:45:54Z","timestamp":1676385954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/43\/3\/281\/6597262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.13357","archive":["Portico"],"relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,12]]}}}